Search Results

There are 7568 results for: content related to: Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions

  1. You have free access to this content
    A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction

    HIV Medicine

    Volume 15, Issue 5, May 2014, Pages: 301–310, J Baril, B Conway, P Giguère, N Ferko, S Hollmann and JB Angel

    Version of Record online : 9 DEC 2013, DOI: 10.1111/hiv.12118

  2. You have free access to this content
    Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir

    HIV Medicine

    Volume 15, Issue 6, July 2014, Pages: 330–338, E Martinez, A Gonzalez-Cordon, E Ferrer, P Domingo, E Negredo, F Gutierrez, J Portilla, A Curran, D Podzamczer, J Murillas, JI Bernardino, I Santos, JA Carton, J Peraire, J Pich, I Perez, JM Gatell and for the ATADAR Study Group

    Version of Record online : 12 JAN 2014, DOI: 10.1111/hiv.12121

  3. A Low Dose of Ritonavir-Boosted Atazanavir Provides Adequate Pharmacokinetic Parameters in HIV-1-Infected Thai Adults

    Clinical Pharmacology & Therapeutics

    Volume 85, Issue 4, April 2009, Pages: 402–408, A Avihingsanon, J van der Lugt, SJ Kerr, M Gorowara, S Chanmano, P Ohata, J Lange, DA Cooper, P Phanuphak, DM Burger and K Ruxrungtham

    Version of Record online : 31 DEC 2008, DOI: 10.1038/clpt.2008.244

  4. You have full text access to this OnlineOpen article
    The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir

    HIV Medicine

    Volume 17, Issue 2, February 2016, Pages: 106–117, DA Wohl, L Bhatti, CB Small, H Edelstein, HH Zhao, DA Margolis, E DeJesus, WG Weinberg, LL Ross and MS Shaefer

    Version of Record online : 14 JUL 2015, DOI: 10.1111/hiv.12281

  5. Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy

    HIV Medicine

    Volume 15, Issue 10, November 2014, Pages: 604–610, LJ Else, V Jackson, M Brennan, DJ Back, SH Khoo, S Coulter-Smith and JS Lambert

    Version of Record online : 14 MAY 2014, DOI: 10.1111/hiv.12164

  6. You have free access to this content
    Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection

    HIV Medicine

    Volume 11, Issue 5, May 2010, Pages: 326–333, M Fabbiani, S Di Giambenedetto, E Ragazzoni, M Colafigli, M Prosperi, R Cauda, P Navarra and A De Luca

    Version of Record online : 11 JAN 2010, DOI: 10.1111/j.1468-1293.2009.00785.x

  7. You have free access to this content
    Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents

    British Journal of Clinical Pharmacology

    Volume 72, Issue 6, December 2011, Pages: 940–947, Frantz Foissac, Stéphane Blanche, Catherine Dollfus, Déborah Hirt, Ghislaine Firtion, Corinne Laurent, Jean-Marc Treluyer and Saïk Urien

    Version of Record online : 9 NOV 2011, DOI: 10.1111/j.1365-2125.2011.04035.x

  8. You have free access to this content
    Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women

    HIV Medicine

    Volume 12, Issue 9, October 2011, Pages: 570–579, F Conradie, C Zorrilla, D Josipovic, M Botes, O Osiyemi, E Vandeloise, T Eley, M Child, R Bertz, W Hu, V Wirtz and D McGrath

    Version of Record online : 16 MAY 2011, DOI: 10.1111/j.1468-1293.2011.00927.x

  9. You have free access to this content
    Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572

    British Journal of Clinical Pharmacology

    Volume 72, Issue 1, July 2011, Pages: 103–108, Ivy Song, Julie Borland, Shuguang Chen, Yu Lou, Amanda Peppercorn, Toshihiro Wajima, Sherene Min and Stephen C. Piscitelli

    Version of Record online : 9 JUN 2011, DOI: 10.1111/j.1365-2125.2011.03947.x

  10. The Effect of Atazanavir and Atazanavir/Ritonavir on UDP-Glucuronosyltransferase Using Lamotrigine as a Phenotypic Probe

    Clinical Pharmacology & Therapeutics

    Volume 84, Issue 6, December 2008, Pages: 698–703, DM Burger, A Huisman, N Van Ewijk, H Neisingh, P Van Uden, GA Rongen, P Koopmans and RJ Bertz

    Version of Record online : 4 JUN 2008, DOI: 10.1038/clpt.2008.106

  11. Pharmacokinetics and Pharmacodynamics of Atazanavir-containing Antiretroviral Regimens, with or without Ritonavir, in Patients who are HIV-positive and Treatment-naïve

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 33, Issue 3, March 2013, Pages: 284–294, Richard J. Bertz, Anna Persson, Ellen Chung, Li Zhu, Jenny Zhang, Donnie McGrath and Dennis Grasela

    Version of Record online : 1 MAR 2013, DOI: 10.1002/phar.1205

  12. You have free access to this content
    Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers

    HIV Medicine

    Volume 8, Issue 7, October 2007, Pages: 457–464, AD Luber, R Brower, D Kim, R Silverman, CA Peloquin and I Frank

    Version of Record online : 23 AUG 2007, DOI: 10.1111/j.1468-1293.2007.00496.x

  13. Evaluation of Atazanavir and Darunavir Interactions with Lipids for Developing pH-Responsive Anti-HIV Drug Combination Nanoparticles

    Journal of Pharmaceutical Sciences

    Volume 103, Issue 8, August 2014, Pages: 2520–2529, Jinghua Duan, Jennifer P. Freeling, Josefin Koehn, Cuiling Shu and Rodney J. Y. Ho

    Version of Record online : 19 JUN 2014, DOI: 10.1002/jps.24046

  14. You have free access to this content
    Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study

    HIV Medicine

    Volume 11, Issue 1, January 2010, Pages: 40–45, R Giuntini, C Martinelli, E Ricci, F Vichi, E Gianelli, G Madeddu, C Abeli, L Palvarini, G Penco, P Marconi, C Grosso, G Pellicano, P Bonfanti and T Quirino

    Version of Record online : 3 AUG 2009, DOI: 10.1111/j.1468-1293.2009.00740.x

    Corrected by:

    ERRATUM

    Vol. 12, Issue 2, 127, Version of Record online: 23 DEC 2010

  15. Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients

    Fundamental & Clinical Pharmacology

    Volume 27, Issue 2, April 2013, Pages: 216–222, Dario Cattaneo, Diego Ripamonti, Sara Baldelli, Valeria Cozzi, Serena Fucile and Emilio Clementi

    Version of Record online : 2 NOV 2011, DOI: 10.1111/j.1472-8206.2011.01005.x

  16. Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen

    HIV Medicine

    Volume 15, Issue 9, October 2014, Pages: 547–556, I Jarrin, B Hernández-Novoa, B Alejos, I Santos, J Lopez-Aldeguer, M Riera, F Gutiérrez, R Rubio, A Antela, JR Blanco, S Moreno and the Cohort of the Spanish HIV Research Network (CoRIS)

    Version of Record online : 23 MAR 2014, DOI: 10.1111/hiv.12144

  17. You have free access to this content
    Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients

    HIV Medicine

    Volume 12, Issue 10, November 2011, Pages: 620–631, SME Vrouenraets, FWNM Wit, E Fernandez Garcia, GJ Moyle, AG Jackson, C Allavena, F Raffi, DT Jayaweera, S Mauss, C Katlama, M Fisher, L Slama, WD Hardy, E DeJesus, A van Eeden, P Reiss and for the BASIC study group

    Version of Record online : 7 AUG 2011, DOI: 10.1111/j.1468-1293.2011.00941.x

  18. You have free access to this content
    Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions

    HIV Medicine

    Volume 15, Issue 4, April 2014, Pages: 224–232, W Tinago, JA O'Halloran, RM O'Halloran, A Macken, JS Lambert, GJ Sheehan and PWG Mallon

    Version of Record online : 12 NOV 2013, DOI: 10.1111/hiv.12107

  19. You have free access to this content
    Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic

    British Journal of Clinical Pharmacology

    Volume 60, Issue 3, September 2005, Pages: 291–299, John E. Ray, Debbie Marriott, Mark T. Bloch and Andrew J. McLachlan

    Version of Record online : 6 MAY 2005, DOI: 10.1111/j.1365-2125.2005.02413.x

  20. Pharmacokinetics of Saquinavir With Atazanavir or Low-Dose Ritonavir Administered Once Daily (ASPIRE I) or Twice Daily (ASPIRE II) in Seronegative Volunteers

    The Journal of Clinical Pharmacology

    Volume 47, Issue 2, February 2007, Pages: 201–208, Dr Jennifer R. King, Dr Thomas N. Kakuda, Ms Sunita Paul, Dr Man Ming Tse, Dr Edward P. Acosta and Dr Stephen L. Becker

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270006296763